SEC Form 4 · accession 0001209191-18-057707
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Keith Wayne Ward
Officer — Chief Development Officer
Period of report
Nov 7, 2018
Accepted (ET)
Nov 8, 2018 · 11:16 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A common stockF2 | Nov 7, 2018 | C | 4,750 | — | A | 4,750 | D | |
| Class A common stockF3 | Nov 7, 2018 | S | 3,697 | $66.64 | D | 1,053 | D | |
| Class A common stockF4 | Nov 7, 2018 | S | 1,053 | $68.13 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F5,F2 | $11.62 | Nov 7, 2018 | M | 4,750 | D | — | Jun 15, 2023 | Class B common stock | 4,750 | 25,287 | D |
| Class B common stockF2 | — | Nov 7, 2018 | M | 4,750 | A | — | — | Class A common stock | 4,750 | 4,750 | D |
| Class B common stockF2 | — | Nov 7, 2018 | C | 4,750 | D | — | — | Class A common stock | 4,750 | 0 | D |
Explanation of responses
- F1The exercise, conversion and sale reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 18, 2017.
- F2The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $66.62 to $67.32. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- F4The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $68.00 to $68.25. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
- F5The options, representing a right to purchase a total of 82,287 shares, vested in twenty equal quarterly installments beginning on September 15, 2013.